Real-world experience of atezolizumab and bevacizumab for treatment of advanced hepatocellular carcinoma in a single tertiary center

被引：0
|
作者：
Raharjo, C. V. [1 ]
Joseph, R. [1 ]
Stratton, E. [1 ]
Levy, M. [1 ,2 ]
Prakoso, E. [1 ,3 ]
机构：
[1] Liverpool Hosp, Dept Gastroenterol, Liverpool, England
[2] Univ New South Wales, Sydney, Australia
[3] Univ Sydney, Sydney, NSW, Australia
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2023年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
106
引用
收藏
页码：22 / 22
页数：1
相关论文
共 50 条
  • [41] Real-world multi-center study of systemic treatment after first-line atezolizumab plus bevacizumab for advanced hepatocellular carcinoma in Asia-Pacific countries
    Lee, C-K.
    Yoo, C.
    Park, S. J.
    Kim, H.
    Korphaisarn, K.
    Kim, J. W.
    Chen, S-C.
    Kim, I.
    Kim, M.
    Chan, S. L.
    Kim, J. W.
    Tai, D. W. M.
    Oh, S. B.
    Chen, C-T.
    Bae, W. K.
    Kim, H.
    Hong, J. Y.
    Choi, H. J.
    Chon, H. J.
    Lee, M. A.
    ANNALS OF ONCOLOGY, 2023, 34 : S603 - S603
  • [42] Letter to the editor: Atezolizumab plus bevacizumab for hepatocellular carcinoma in the real world
    Zhang, Junwei
    Fang, Jinyu
    Xun, Ziyu
    Xu, Yiyao
    Lu, Xin
    Zhao, Haitao
    HEPATOLOGY, 2022, 76 (04) : E84 - E85
  • [43] Atezolizumab and bevacizumab for hepatocellular carcinoma: How to approach salvage therapy for non-responders?: Editorial on "Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study"
    Nishida, Naoshi
    CLINICAL AND MOLECULAR HEPATOLOGY, 2024, 30 (04)
  • [44] Letter to the editor on "Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/ bevacizumab failure: A real-world study"
    Wu, Meng-Che
    Chang, Hui-Chin
    Jhang, Yi-Sheng
    Gau, Shuo-Yan
    CLINICAL AND MOLECULAR HEPATOLOGY, 2025, 31 (01)
  • [45] Clinical effects and emerging issues of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma from Japanese real-world practice
    Nakagawa, Miyuki
    Inoue, Masanori
    Ogasawara, Sadahisa
    Maruta, Susumu
    Okubo, Tomomi
    Itokawa, Norio
    Iino, Yotaro
    Obu, Masamichi
    Haga, Yuki
    Seki, Atsuyoshi
    Kikuchi, Yasuharu
    Kogure, Tadayoshi
    Yumita, Sae
    Ishino, Takamasa
    Ogawa, Keita
    Fujiwara, Kisako
    Iwanaga, Terunao
    Fujita, Naoto
    Sakuma, Takafumi
    Kojima, Ryuta
    Kanzaki, Hiroaki
    Koroki, Keisuke
    Taida, Takashi
    Kobayashi, Kazufumi
    Kiyono, Soichiro
    Nakamura, Masato
    Kanogawa, Naoya
    Kondo, Takayuki
    Nakagawa, Ryo
    Nakamoto, Shingo
    Muroyama, Ryosuke
    Chiba, Tetsuhiro
    Itobayashi, Ei
    Atsukawa, Masanori
    Koma, Yoshihiro
    Azemoto, Ryosaku
    Ito, Kenji
    Mizumoto, Hideaki
    Shinozaki, Masami
    Kato, Jun
    Kato, Naoya
    CANCER, 2023, 129 (04) : 590 - 599
  • [46] Real-world experience with Lenvatinib in the management of Hepatocellular Carcinoma: A single-center Indian experience.
    Rauthan, Amit
    Somashekhar, S. P.
    Patil, Poonam
    Zaveri, Shabber
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [47] Real-world evidence of sorafenib for the treatment of hepatocellular carcinoma: A single-center study
    Lopez-Lopez, Aida
    Gayoso-Rey, Monica
    Garcia-Beloso, Nerea
    Romero-Ventosa, Yaiza
    Robles-Torres, David
    Martinez-Reglero, Cristina
    Pineiro-Corrales, Guadalupe
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2023, 19 (05) : 1345 - 1349
  • [48] Significance of ramucirumab following atezolizumab plus bevacizumab therapy for hepatocellular carcinoma using real-world data
    Shimose, Shigeo
    Sugimoto, Rie
    Hiraoka, Atsushi
    Tanaka, Masatoshi
    Iwamoto, Hideki
    Tanaka, Yuki
    Tada, Fujimasa
    Ohama, Hideko
    Niizeki, Takashi
    Shirono, Tomotake
    Moriyama, Etsuko
    Noda, Yu
    Kamachi, Naoki
    Nakano, Masahito
    Kuromatsu, Ryoko
    Koga, Hironori
    Kawaguchi, Takumi
    HEPATOLOGY RESEARCH, 2023, 53 (02) : 116 - 126
  • [49] Atezolizumab/bevacizumab or lenvatinib in hepatocellular carcinoma: Multicenter real-world study with focus on bleeding and thromboembolic events
    Ben Khaled, Najib
    Moeller, Marie
    Jochheim, Leonie S.
    Leyh, Catherine
    Ehmer, Ursula
    Boettcher, Katrin
    Pinter, Matthias
    Balcar, Lorenz
    Scheiner, Bernhard
    Weich, Alexander
    Leicht, Hans Benno
    Zarka, Valentina
    Ye, Liangtao
    Schneider, Julia
    Piseddu, Ignazio
    Oecal, Osman
    Rau, Monika
    Sinner, Friedrich
    Venerito, Marino
    Gairing, Simon Johannes
    Foerster, Friedrich
    Mayerle, Julia
    Toni, Enrico N. De
    Geier, Andreas
    Reiter, Florian P.
    JHEP REPORTS, 2024, 6 (06)
  • [50] Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study
    Mara Persano
    Margherita Rimini
    Toshifumi Tada
    Goki Suda
    Shigeo Shimose
    Masatoshi Kudo
    Jaekyung Cheon
    Fabian Finkelmeier
    Ho Yeong Lim
    Lorenza Rimassa
    José Presa
    Gianluca Masi
    Changhoon Yoo
    Sara Lonardi
    Francesco Tovoli
    Takashi Kumada
    Naoya Sakamoto
    Hideki Iwamoto
    Tomoko Aoki
    Hong Jae Chon
    Vera Himmelsbach
    Tiziana Pressiani
    Takumi Kawaguchi
    Margarida Montes
    Caterina Vivaldi
    Caterina Soldà
    Fabio Piscaglia
    Atsushi Hiraoka
    Takuya Sho
    Takashi Niizeki
    Naoshi Nishida
    Christoph Steup
    Massimo Iavarone
    Giovanni Di Costanzo
    Fabio Marra
    Mario Scartozzi
    Emiliano Tamburini
    Giuseppe Cabibbo
    Francesco Giuseppe Foschi
    Marianna Silletta
    Masashi Hirooka
    Kazuya Kariyama
    Joji Tani
    Masanori Atsukawa
    Koichi Takaguchi
    Ei Itobayashi
    Shinya Fukunishi
    Kunihiko Tsuji
    Toru Ishikawa
    Kazuto Tajiri
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 5591 - 5602
12345